Corporate Governance2 Nov 2026, 08:24 pm
Sun Pharma Advanced Research: Monitoring Agency Report Q3 2026
AI Summary
Sun Pharma Advanced Research Company Ltd has submitted its Monitoring Agency Report for the quarter ended September 30, 2026. The report, issued by Acuité Ratings and Research Limited, confirms no deviation in the utilization of proceeds from the Preferential Issue of Warrants. The utilization aligns with the disclosures made in the Offer Document. The issue size was ₹599.98 Crore, with the issue period from May 8, 2026, to May 23, 2026. The report indicates no unfavorable events affecting the viability of the objects and no other relevant information that could materially affect investor decision-making.
Key Highlights
- No deviation in utilization of preferential issue proceeds.
- Utilization is in line with the Offer Document disclosures.
- No material unfavorable events affecting project viability.
- Report covers the quarter ended September 30, 2026.
Price Impact
More from SPARC